Intervention Protocol

You have free access to this content

Vaccines for preventing influenza in multiple sclerosis patients

  1. Carlo Di Pietrantonj1,*,
  2. Alessandro Rivetti1,
  3. Claudia Baiocchi2,
  4. Adnaan Haq3

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group

Published Online: 1 JUL 2013

Assessed as up-to-date: 24 MAY 2013

DOI: 10.1002/14651858.CD010603


How to Cite

Di Pietrantonj C, Rivetti A, Baiocchi C, Haq A. Vaccines for preventing influenza in multiple sclerosis patients (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010603. DOI: 10.1002/14651858.CD010603.

Author Information

  1. 1

    Azienda Sanitaria Locale ASL AL, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Alessandria, Piemonte, Italy

  2. 2

    MS Consumer, Milano, Italy

  3. 3

    St. George's University of London, Medical School, London, UK

*Carlo Di Pietrantonj, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Azienda Sanitaria Locale ASL AL, Via Venezia 6, Alessandria, Piemonte, 15100, Italy. cdipietrantonj@aslal.it.

Publication History

  1. Publication Status: New
  2. Published Online: 1 JUL 2013

SEARCH

References

Additional references

ACIP 2010
  • Centers for Diseases Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2010;59(RR-8):1-62.
Andersen 1993
CCDR 2012
  • National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2012-2013. Canada Communicable Disesases Report August 2012;38(ACS-2):1-36.
CDC 2012
  • Centers for Diseases Control. Prevention and control of influenza with vaccines: reccomandations of the Advisory Commitee on Immunization Practice (AICP) United States, 2012-2013 Influenza Season. Morbidity and Mortality Weekly Report 2012, August 17;61(32):613-8.
D'hooghe 2010
  • D'Hooghe MB, Nagel G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. Multiple Sclerosis 2010, May 18;doi 10.1177/1352458510367721:1-10.
Edwards 1998
  • Edwards, ZvartauM, Clarke H, Irving W, Blumhardt LD. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1998;64:736-41.
Fischer 1999
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011; Vol. Available from www.cochrane-handbook.org.
Jefferson 2010a
  • Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD001269.pub4]
Jefferson 2010b
  • Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD004876.pub3]
Jeffery 2002
  • Jeffery DR. The use of vaccinations in patients with multiple sclerosis. 2002 Cliggott Publishing, Division of CMP Healthcare Media May 19, 2002:http://www.medscape.com/viewarticle/429479.
Kurtzke 1983
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-11.
Maclure 1991
McDonald 2001
MSC 2001
  • Multiple Sclerosis Council for Clinical Practice Guideline. Immunizations and multiple sclerosis - Evidence-based management strategies for immunizations in multiple sclerosis patients. Clinical Practice Guideline November 2001.
Noseworthy 2000
Panitch 1994
Polman 2005
Polman 2011
Poser 1983
Review Manager 2012 [Computer program]
  • Version 5.2 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rutschmann 2002
Schumacher 1965
Sibley 1965
Sibley 1985
STIKO 2004
  • Ständige Impfkommission (STIKO). Rationale for influenza immunisation recommendations of MS-Patients with relapse episodes triggered through infections [Begründung der STIKO für die Influenza-Impfung bei Patienten mit Multipler Sklerose mit durch Infektionen getriggerten Schüben]. Epidemiologisches Bulletin (Robert Koch Institut) 2004;32:261-8.
Stratton 2004
  • Stratton K, Alamario D, Wizemann T, McCormick, Immunization Safety Review Committee. In: Immunization Safety Review Committee, editor(s). Immunization Safety Review - Influenza Vaccines and Neurological Complications. http://www.nap.edu/catalog.php?record_id=10822: National Academy of Sciences, 2004.
The Australian Immunization Handbook 2008
  • Australian Technical Advisory Group on Immunization (ATAGI). 3.9 Influenza. The Australian Immunisation Handbook 9th Edition 2008;http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home:1.
UK GreenBook 2012
  • Salisbury D, Ramsay M, Noakes K (editors). Immunisation against infectious disease. Green Book. http://immunisation.dh.gov.uk/green-book-chapters/chapter-19/: Department of Health, 2012, August 24.
Vickrey 1997
  • Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. Journal of Clinical Epidemiology 1997;50(5):557-69.